Evaluation of Oxidative Stress and Effect of Levothyroxine Treatment on Oxidative Stress in Hashimoto Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01102205
: April 13, 2010
Last Update Posted
: June 13, 2013
Vakif Gureba Training and Research Hospital
Information provided by (Responsible Party):
Mehmet Ali Cikrikcioglu, Vakif Gureba Training and Research Hospital
Oxidative stress leads to or accompanies with numerous disease. Oxidative balance in subclinical hypothyroid or euthyroid state in Hashimoto disease are not known. Effect of levothyroxine therapy on oxidative balance are also not known in hashimoto disease.
Condition or disease
oxidative stress markers will be measured initially(TAS,TOS,OSI,PARAOXONASE,ARYLESTERASA,PON1 PHENOTYPİNG,LİPİDPEROXİD).After 3 months therapy with levothyroxine measurements will be repeated except PON1 phenotyping.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 95 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
adult with Hashimoto disease in euthyroid or subclinical hypothyroid state and healthy control.
age more than 18 years
inability to give a written consent
other conditions and drug usage affect oxidative stress